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DObjective: The modified Blalock-Taussig shunt is the most commonly used palliative procedure for infants with
ductal-dependent pulmonary circulation. Recently, catheter-based stenting of the ductus arteriosus has been
used by some centers to avoid surgical shunt placement. We evaluated the durability and safety of ductal stenting
as an alternative to the modified Blalock-Taussig shunt.
Methods: A single-institution, retrospective review of patients undergoing modified Blalock-Taussig shunt
versus ductal stenting was performed. Survival, procedural complications, and freedom from reintervention
were the primary outcome variables.
Results: A total of 42 shunted and 13 stented patients with similar age and weight were identified. Survival to
second-stage palliation, definitive repair, or 12 months was similar between the 2 groups (88% vs 85%;
P ¼ .742). The incidence of surgical or catheter-based reintervention to maintain adequate pulmonary blood
flow was 26% in the shunted patients and 25% in the stented patients (P ¼ 1.000). Three shunted patients
(7%) required intervention to address contralateral pulmonary artery stenosis and 3 (7%) required surgical
reintervention to address nonpulmonary blood flow-related complications. The need for ipsilateral or juxtaductal
pulmonary artery intervention at, or subsequent to, second-stage palliation or definitive repair was similar
between the 2 groups.
Conclusions: Freedom from reintervention to maintain adequate pulmonary blood flow was similar between
infants undergoingmodified Blalock-Taussig shunt or ductal stenting as an initial palliative procedure. However,
a greater percentage of shunted patients experienced procedure-related complications and distal branch
pulmonary artery stenosis. Palliative ductal stenting appears to be a safe and effective alternative to modified
Blalock-Taussig in selected infants. (J Thorac Cardiovasc Surg 2014;147:397-403)CThe modified Blalock-Taussig systemic-to-pulmonary
shunt (mBTS) is the most commonly used palliative
procedure for infants with ductal-dependent pulmonary
blood flow. Although the mBTS generally provides a
reliable and regulated source of pulmonary blood flow,
patients remain at risk of early and late shunt occlusion.1,2
Surgical shunt revision or catheter-based intervention to
maintain or re-establish shunt patency has been required
in a significant number of patients. In recent years,
percutaneous transcatheter placement of a stent to maintain
ductal patency has been used by some centers as an
alternative method to provide a source of pulmonary bloodhe Division of Pediatric Cardiac Surgerya and Division of Pediatric
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The Journal of Thoracic and Caflow.3,4 The potential advantages of ductal stenting (DS)
include reduced procedure-related risks, avoidance of
cardiopulmonary bypass, and improved distribution of
pulmonary artery blood flow. We reviewed our initial
experience with DS as an alternative to mBTS in selected
patients to determine the safety and effectiveness of this
novel approach.METHODS
A retrospective review of patients who had undergone cardiac surgery or
cardiac catheterization at Seattle Children’s Hospital from December 2002
to April 2011 was performed after receiving approval from the hospital’s
institutional review board. During this period, 3,133 surgical procedures
and 4,100 catheterization procedures were performed. A focused review
of the medical records and procedure summaries was undertaken for
42 patients (median age, 12 days; range, 2-218) who had undergone
placement of a mBTS and 13 patients (median age, 13 days; range, 4-43)
who had undergone percutaneous implantation of a DS to maintain patency
of the ductus arteriosus and provide a source of pulmonary blood flow. The
patients who had undergone DS implantation as a part of a hybrid palliation
(ductal stent plus balloon atrial septostomy plus bilateral pulmonary artery
bands) for single-ventricle heart disease and the patients who had
undergone placement of a mBTS and a concomitant cardiac surgical
procedure, including pulmonary artery augmentation, were excluded
from the present analysis. The patients who had undergone concomitant
cardiac surgical procedures were excluded from the analysis because DS
alone would not have been a realistic therapeutic option. The selection ofrdiovascular Surgery c Volume 147, Number 1 397
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DmBTS versus DS for each patient was individualized and determined by the
estimated procedural risk, appropriateness of the pulmonary artery and/or
ductus arteriosus anatomy, and patient comorbidities. The exclusion
criteria for DS included discontinuous branch pulmonary arteries, an origin
of either branch pulmonary artery from the ductus arteriosus, branch
pulmonary artery stenosis, weight 2 kg (inadequate vascular access),
and a concomitant need for cardiopulmonary bypass or an open surgical
procedure. The tortuosity of the ductus arteriosus was not a contraindi-
cation. Data collection was terminated after second-stage palliation,
definitive repair, or 12 months after mBTS or DS.Modified Blalock-Taussig Shunt
The procedure to construct an mBTS was performed as described by de
Leval and colleagues.5 Cardiopulmonary bypass was used in 8 patients
(19%) who had exhibited hemodynamic instability or significant desatura-
tion during the procedure. Heparin (100 U/kg) was administered before
vascular exclusion and shunt placement in the patients who did not require
cardiopulmonary bypass. The location and course of the shunt was
determined by anatomic considerations, including aortic arch sidedness
and the location of the ductus arteriosus. mBTS placement was performed
through a median sternotomy in all patients. The mBTS was based on the
right innominate or subclavian artery in 37 patients (88%) and the left
subclavian artery in the remaining 5 (12%). The expanded polytetrafluo-
roethylene shunt diameter was either 3.5 mm (n ¼ 13, 31%) or 4 mm
(n¼ 29, 69%) depending on the size of the patient and the proximal branch
pulmonary arteries. In the setting of a patent ductus arteriosus, concomitant
ductal ligation was performed when adequate systemic saturation was
observed after a brief period of temporary ductal occlusion. A patent ductus
arteriosus was present in 26 of the 42 patients (62%), of whom 20 (77%)
underwent concomitant ductal ligation. Primary sternal closure was
performed at surgery in all patients.Ductal Stenting
Standard left and right heart cardiac catheterization was performed with
the patient under general anesthesia and using femoral vascular access. The
preferred stent deployment was in a prograde fashion using femoral venous
access. In patients with pulmonary atresia and an intact ventricular septum,
determination of right ventricular-dependent coronary circulation was
performed. Percutaneous pulmonary valve perforation and subsequent
prograde stent deployment was completed in the absence of right
ventricular-dependent coronary circulation. Retrograde stent deployment
was performed when the anatomic features prevented prograde
deployment. Once vascular access was established, 3.5-mm (n ¼ 1),
4-mm (n ¼ 14), or combined 3.5- and 4.0-mm MULTI-LINK VISION
(Abbott Laboratories, Abbott Park, Ill), premounted coronary stents were
deployed within the ductus arteriosus. Patients received 1 (n ¼ 4), 2
(n ¼ 7), or 3 (n¼ 2) stents to establish adequate ductal patency. The stents
were positioned such that 1 to 2 mm of stent material extended into the
pulmonary artery confluence and beyond the ductal ampulla of the aorta.
The ductal stents were placed such that approximately 20% to 30% of
the stent was protruding into the aorta to prevent juxta-aortic ductal
involution, which can lead to stenosis. Ligation of the stented ductus
arteriosus was performed in 4 patients at definitive surgical repair or
palliation. Ductal ligation alone was performed in 1 patient, and ligation398 The Journal of Thoracic and Cardiovascular Surgand division of the ductus arteriosus was performed in 3 patients. Ductal
ligation was performed with braided nylon suture, and the stented ductus
was divided with scissors without difficulty. Mobilization and vascular
control of the aorta were not necessary. When division of the ductus
arteriosus was performed, the portion of the stent within the pulmonary
artery was excised, and the small defect in the pulmonary artery was closed
with a patch of autologous pericardium.
In the mBTS and DS groups, the primary indication for palliation was as
follows: double outlet right ventricle in 7 (17%) and 0 patients (P¼ .179),
tetralogy of Fallot in 7 (17%) and 1 (8%) patient (P ¼ .664), pulmonary
atresia in 12 (29%) and 8 (62%; P ¼ .048), Ebstein’s anomaly in 3
(7%) and 0 (P ¼ 1.000), tricuspid atresia in 4 (10%) and 0 (P ¼ .562),
complex arterial transposition in 8 (19%) and 2 (15%; P ¼ 1.000), and
unbalanced atrioventricular septal defect in 1 (2%) and 2 (15%) patients
(P ¼ .136; Table 1).
The data are presented as the median and range or numbers and
percentages. Statistical analysis of the categorical variables was conducted
using Fisher’s exact test. The groups were compared by unpaired t tests
for continuous variables. Survival analysis was performed using the
Kaplan-Meier method, and a comparison of the survival curves was
performed using the log-rank test. Analyses were performed using SPSS
Statistics, version 19 (IBM, Armonk, NY), with P < .05 considered
statistically significant. All reported P values are 2-sided.RESULTS
No procedure-related deaths occurred in either group.
The 30-day survival was 98% in the mBTS group and
92% in the DS group (P ¼ .371). One mBTS patient died
of irreversible bradycardia related to airway suctioning on
the first postoperative day, and 1 DS patient died of
multisystem organ failure on postprocedure day 5. The
overall median follow-up was 189 days (range, 1-365;
196 days for mBTS vs 121 days for DS; P ¼ .347). The
overall survival to second-stage palliation, definitive repair,
or 12 months was 87% (88%mBTS vs 85%DS, P¼ .742).
During the 1-year follow-up period, second-stage palliation
or definitive repair was performed in 27 patients (64%) in
the mBTS group and 6 patients (38%) in the DS group
(P ¼ .334). The overall median interval to second-stage
palliation or definitive repair was 189 days (range,
13-365; 198 days for mBTS vs 130 days for DS;
P ¼ .197; Table 2). The initial postprocedural systemic
oxygen saturation was similar between the 2 groups
(mBTS, 83%; range, 72%-97% vs DS, 87%; range,
68%-95%; P ¼ .077).
An interval reintervention to maintain adequate pulmo-
nary blood flow was performed in 11 patients (26%) in
the mBTS group and 3 patients (25%) in the DS group
(P ¼ 1.000). The median interval to reintervention was
14 days (range, 1-121) in the mBTS group and 69 days
(range, 4-146) in the DS group (P ¼ .287). Multiple
reinterventions to maintain adequate pulmonary blood
flow were required in 3 mBTS patients (7%). No DS
patients required >1 reintervention. Reintervention to
maintain adequate pulmonary blood flow in the mBTS
group included early surgical repair of tetralogy of Fallot
with a transannular patch in 1, early bidirectional Glennery c January 2014
TABLE 1. Comparison of patients undergoing modified Blalock-
Taussig shunt and ductal stenting
Variable
mBTS
(n ¼ 42)
DS
(n ¼ 13)
P
value
Age (d) 12 (2-218) 13 (4-43) .147
Weight (kg) 3.3 (2.3-8.6) 3.3 (2.0-4.5) .339
Diagnostic indication
Double outlet right ventricle 7 (17) 0 (0) .179
Tetralogy of Fallot 7 (17) 1 (8) .664
Pulmonary atresia 12 (29) 8 (62) .048
Ebstein’s anomaly 3 (7) 0 (0) 1.000
Tricuspid atresia 4 (10) 0 (0) .562
Complex arterial transposition 8 (19) 2 (15) 1.000
Unbalanced atrioventricular canal 1 (2) 2 (15) .136
Data presented as median (range) or n (%). mBTS, Modified Blalock-Taussig
systemic-to-pulmonary shunt; DS, ductal stenting.
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Dshunt placement in 1, balloon dilation of the shunt in 3,
stenting of the shunt in 6, mBTS revision in 1, patent ductus
arteriosus ligation in 1, and stenting of the central
pulmonary artery in 1 patient. The indications for reinter-
vention in the mBTS group included thrombotic occlusion
of the shunt (n ¼ 4) at 0, 0, 12, and 26 days, distal shunt
narrowing (n ¼ 3) at 14, 63, and 115 days, proximal shunt
narrowing (n¼ 1) at 121 days, shunt distortion (n ¼ 1) at 1
day, patent ductus arteriosus ligation (n¼ 1) at 47 days, and
central (juxtaductal) pulmonary artery narrowing (n¼ 1) on
the day of shunt placement. Juxtaductal narrowing of the
right pulmonary artery appeared to be related to local
distortion of the otherwise anatomically normal structure.
Two patients in the DS group required placement of
additional ductal stents, and one patient required mBTS
on postprocedure day 69 because of complete occlusion
of the ductal stent, presumably caused by ductal tissue
neointimal proliferation. This patient subsequently under-
went definitive surgical repair (Nikaidoh aortic trans-
location) 375 days later, without requiring mBTS
reintervention. At second-stage palliation or definitiveTABLE 2. Comparison of endpoint variables stratified by group
Variable
mBTS
(n ¼ 42)
DS
(n ¼ 13)
P
value
30-d Survival 98 92 .371
Overall survival 88 85 .742
Follow-up period (d) 196 (1-365) 121 (5-365) .347
Procedural complications 3 (7) 0 1.000
Interval ipsilateral/juxtaductal
reintervention
11 (26) 3 (25) 1.000
Interval to ipsilateral/juxtaductal
reintervention (d)
14 (1-121) 69 (4-146) .287
Contralateral and/or distal intervention 3 (7) 0 1.000
Ipsilateral or juxtaductal intervention
at staged palliation or repair
6 (22) 1 (17) .488
Data presented as %, median (range), or n (%). mBTS, Modified Blalock-Taussig
systemic-to-pulmonary shunt; DS, ductal stenting.
The Journal of Thoracic and Carepair, 4 patients (15%) in the mBTS group required patch
augmentation of the ipsilateral pulmonary artery and 2
(7%) required balloon angioplasty of the ipsilateral branch
pulmonary artery within 30 days of repair. One patient
(17%) in the DS group required patch augmentation
of the juxtaductal proximal right pulmonary artery at
placement of a Glenn shunt (P ¼ .488). The actuarial
freedom from interval reintervention was similar between
the 2 groups (log rank test, P ¼ .914; Figure 1).
Interventions to address clinically significant contra-
lateral (juxtaductal) pulmonary artery narrowing were
required in 3 mBTS patients (7%). Two patients required
stenting of the contralateral branch pulmonary artery at 3
and 7 days after mBTS. Multiple percutaneous reinterven-
tions were required to maintain adequate contralateral
pulmonary artery flow in both patients. The third patient
required left pulmonary artery patch augmentation at
second-stage palliation. No patient in the DS group required
an intervention to address distal, nonjuxtaductal narrowing.
One mBTS patient (2%) required surgical exploration to
address perioperative bleeding. Two mBTS patients (5%)
required surgical wound exploration to address localized
infection or deep mediastinitis. One patient in the DS group
who required an mBTS to address complete stent occlusion
developed a localized perioperative wound infection after
mBTS placement. An additional DS patient experienced
temporary femoral artery occlusion that responded to
systemic heparin therapy. The vessel was patent at
discharge, and the patient received 6 weeks of aspirin
therapy.
Preoperative measurements of the branch pulmonary
arteries were not performed before mBTS because pre-
operative angiography was not routinely performed at our
institution. Angiographic pulmonary artery measurements
obtained at the subsequent Glenn procedure or complete
repair suggested that individual branch pulmonary arteryFIGURE 1. Kaplan-Meier curve comparing freedom from reintervention
to maintain adequate pulmonary blood flow in patients receiving modified
Blalock-Taussig systemic-to-pulmonary shunt (mBTS; dark lines) or ductal
stenting (DS; light lines; P ¼ .914).
rdiovascular Surgery c Volume 147, Number 1 399
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Dgrowth was not affected by ipsilateral mBTS placement
(7.3 mm for the right pulmonary artery vs 7.7 mm for the
left pulmonary artery; P ¼ .551). Similarly, DS did not
appear to discrepantly affect branch pulmonary artery
growth (8.7 mm for the right pulmonary artery vs 8.0 mm
for the left pulmonary artery; P ¼ .637).
DISCUSSION
Early primary surgical repair has been increasingly
adopted in the treatment of neonates with congenital
heart defects that include ductal-dependent pulmonary
circulation and infants with inadequate pulmonary blood
flow. However, the mBTS remains the most common
palliative procedure for patients with complex intracardiac
lesions and patients with inadequate right ventricular
development who will proceed down a singe-ventricle
(Fontan) pathway. Clinical data from >1,700 mBTS
patients have been collected in the Society of Thoracic
Surgeons (STS) Congenital Heart Surgery Database since
2003,6 with reported early survival approaching 93%.7
In addition to the increased risk of perioperative mortality
(approximately 33% of early deaths occur within
24 hours postoperatively), 11% to 13% experience peri-
operative morbidity.1,7 Progressive shunt stenosis occurs
in essentially all patients, with life-threatening shunt
occlusion complicating the course of a small percentage.1
Catheter-based interventions, including balloon angio-
plasty, stent implantation, and directed thrombolytic
therapy, have been used to re-establish mBTS patency for
decades, with an overall success rate of 90%.8
Introduced in 1992,3 percutaneous stenting of the ductus
arteriosus has been used by a number of centers to provide
initial palliation for duct-dependent lesions9 and as rescue
therapy for late mBTS occlusion.2 Compared with mBTS,
evidence has shown that DS might provide a more evenly
distributed pulmonary artery blood flow and promote
more balanced growth of the pulmonary arteries.9 Of the
mBTS patients in our study, 3 required surgical or
catheter-based interventions to address clinically important
narrowing of the contralateral branch pulmonary artery.
Although the narrowing appeared to be primarily related
to involution of the ductal tissue within the pulmonary
artery confluence, 2 of the patients required additional
catheter-based interventions to address more distal
narrowing that was remote from the ductal insertion site.
Pulmonary artery narrowing remote from the ductal
insertion site was not observed in any of the DS patients
in our study, supporting the notion that the choice of
mBTS or DS affects pulmonary artery development beyond
the site of mBTS or DS insertion.
The overall reintervention rate in the present study was
similar to the 21% overall early reintervention rate reported
in a review by Yuan and colleagues10 but greater than
the 8% same-admission reoperation rate for mBTS patients400 The Journal of Thoracic and Cardiovascular Surgreported in the STS Congenital Heart Surgery Database.7
However, the data reported to the STS database have been
limited to surgical reintervention only. Only 1 patient in
the mBTS group underwent surgical reintervention
during the same admission (2% early surgical reinterven-
tion rate), but 2 additional patients underwent early
second-stage palliation (7% overall surgical reintervention
rate). The decision to undertake surgical versus percuta-
neous reintervention to address shunt and pulmonary blood
flow issues will undoubtedly be influenced by an individual
institution’s programmatic philosophy. An important
limitation of the STS data registry is that it does not capture
nonsurgical reintervention data, limiting the ability to
perform comprehensive procedure-to-procedure compari-
sons. The median interval to reintervention (14 days) for
the mBTS patients was similar to that reported by O’Connor
and colleagues11 (12 days). Although we observed a trend
toward an earlier need for reintervention to maintain
appropriate pulmonary blood flow in the mBTS patients,
the reintervention rate was essentially the same for the 2
groups. Evidence has shown that the need for surgical or
transcatheter reintervention to maintain mBTS patency is
associated with significantly lower long-term survival.11
Whether a similar association exists between reintervention
and DS is unknown.
Although the present study was underpowered to
demonstrate a significant difference in procedure-related
complication rates, all the procedure-related complications
occurred in the mBTS group. With all other outcome
endpoints being similar, the observed trend toward
increased procedure-related complications in the mBTS
patients could become an important consideration in the
choice of initial palliation for ductal-dependent lesions.
Our patient selection strategy for DS was determined by
echocardiographic evidence of confluent and adequately
sized branch pulmonary arteries and catheter-based data
regarding the presence of branch pulmonary artery stenosis.
The tortuosity of the ductus arteriosus was not considered a
contraindication to stent deployment. Patient selection bias
was an obvious limitation of our study. However, our
programmatic approach has generally been to perform DS
in patients considered to be at increased risk of surgical
complications. The use of DS in selected patients eliminates
the risks associated with the use of cardiopulmonary bypass
and reduces the risk of open procedure-related infection.
The mBTS remains the most common palliative
procedure for lesions with ductal-dependent pulmonary
circulation. Despite reduced usage of mBTS in recent years,
increased operative survival has been observed in patients
with increasingly complex cases.12 The results of the
present study suggest that DS is a safe and reliable
alternative to mBTS for patients who might be at
increased risk of surgical complications. Additional studies
are needed to identify the anatomic and physiologicery c January 2014
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Dcharacteristics to assist in appropriate patient selection.
The results of the present study should provide surgeons
and interventional cardiologists with a framework from
which to explore alternative strategies for treating patients
with ductal-dependent pulmonary circulation.
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Dr Ross Ungerleider (Winston-Salem, NC). Very nice. You are
a cardiologist, right?
Dr Rubio. I am.
Dr Ungerleider. Give him the applause. It must take a lot of
courage to come to a surgical meeting.
Dr Rubio. It is a little intimidating, but we will see.
Dr Ungerleider. Hang onto that courage right now. I have a
couple questions for you.
It is interesting. If you put it in perspective, the Blalock-Taussig
shunt was probably considered by many to be what started cardiac
surgery, and then prostaglandins came along, and they took the
word ‘‘emergency’’ out of shunting. Now cardiologists are coming
along andmight be taking theword ‘‘surgical’’ out of shunting.My
first question for you really centers on that. We continue to evolve
new methods to approach old problems, and we call this innova-
tion. Although, as you mentioned, the concept of ductal stenting
is not new, the application of ductal stents as a method to
palliate patients who would more traditionally be treated withThe Journal of Thoracic and Caaortopulmonary shunts is a little bit novel. Now, without innova-
tive thinking, we would just keep doing what we have always
done and keep getting what we have always gotten; thus, I applaud
you for this effort. However, philosophically and ethically, it does
beg a question. When does innovation become human experimen-
tation? More specifically, how did your patients give consent?
Were they given surgical and interventional options? Did they
know that this was a nonstandard option?Who did the consent pro-
cess? Were the decisions made by the entire team, and, in fact, did
you need to have institutional review board approval?
Dr Rubio. Thank you for the questions, Dr Ungerleider. The
discussion about the option for an interventional approach instead
of a surgical approach is a decision that is made in a general con-
ference with consultation from the cardiothoracic surgeons, cardi-
ologists, and interventional cardiologists. It is a team decision that
is made, and that team decision is taken to the family as an option.
The surgical reference standard, what I call the reference standard,
the option of surgery for systemic to pulmonary arterial communi-
cation, is always the one presented first. Second, if other comorbid-
ities are present that would make the patient a less than suitable
candidate for bypass in case it might be needed, the discussion
of a nontraditional—I do not like to use the word ‘‘experimental,’’
because this is not an experimental use, but rather the nontradi-
tional use of coronary stenting, in this case stenting of the duc-
tus—is given to the parents. Expectations are also given as to
what type of follow-up will be needed.
Dr Ungerleider. I am just curious. Do you need institutional re-
view board approval in your institution to do nonstandard therapy?
Dr Rubio. No, we do not.
Dr Ungerleider. The next question—you did so well, I am
going to give you another one. This is more related to the indica-
tions for this. You did mention Gibbs’ pioneering work in this, and,
actually a member of this organization, Len Bailey, writing an
editorial about that in 1999, heralded your work by calling this a
‘‘wannabe’’ Blalock-Taussig shunt. However, the prevailing
thought at that time was that coronary stents were really not suited
for the somewhat tortuous and anatomically more difficult ducti
you see in the ductal-dependent lesions that are not hypoplastic
left heart syndrome. You very nicely listed the potential complica-
tions of the Blalock-Taussig or aortopulmonary shunt. You did not
really list them for ductal stents. Now you only had 13 or so—your
numbers are small—but the complications or, as I like to call them,
the consequences, of ductal stents have been well written. They
have included malposition, restenosis, the need sometimes for
multiple stents, erosion, the loss of vessels in the leg that might
one day be necessary, and the technical demands. Those have
been well described. Thus, the question I have for you really re-
volves around the important decision making as we enter this
era of collaboration among cardiologists, interventional cardiolo-
gists, and surgeons, and you certainly seem to have a tendency to
place these stents in patients with pulmonary atresia, so the ques-
tion is, who are the patients who seem most suitable for this? Are
they the patients with pulmonary atresia and a ventricular septal
defect or those with pulmonary atresia and an intact septum?
Tell us from your experience, as we start to consider this as an op-
tion, which of the patients would be the ones who we really should
be thinking most about this?
Dr Rubio. With regard to the ideal patient for this, from my
experience and the experience we have had at our institution, therdiovascular Surgery c Volume 147, Number 1 401
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intact ventricular septum. These patients typically have a hypo-
plastic right ventricle. However, if they are able to demonstrate
with echocardiographic evidence a tricuspid valve annulus that
is<3 standard deviations away from the norm or we are able to
delineate that there is a bipartite right ventricle, a pulmonary at-
retic valve that is reachable by cardiac catheterization safely,
and an ability to establish prograde flow from the right ventricle
into the pulmonary artery, we believe that those patients will be
better candidates for prograde deployment of these coronary
stents. Taking into account the many complications and quirks
that these patients with pulmonary atresia have regarding their
ducti, it does take a certain skill set to be able to be comfortable
in deploying these stents. Stents have been deployed down the de-
scending aorta. They have been deployed into the pulmonary
valve. They have been known, if you are not careful, to exclude
1 of the branch pulmonary arteries. Vascular access is always a
problem. Retrograde approaches are the most difficult and the
ones associated with the most vascular occlusions. The prograde
approach is not as complicated. Those would be the ideal patients.
Dr Ungerleider. It all sounds scary. I still like the idea of an
outflow patch and a shunt. Thank you for sharing this. This is a
very innovative technique that we will all pay attention to.
Dr John Chen (Honolulu, Hawaii). Dr Rubio, you should be
congratulated on your excellent results, remembering that most
of these patients, I presume, weigh 3 kg. I guess my question
is have you followed up these patients or had the opportunity to
follow-up these patients in the long term as to what happens to
these shunts and have you come across a situation in which you
had to ligate a shunt later on that had been stented? What do
you do in that situation?
Dr Rubio. We have been able to follow-up a few of these pa-
tients in the long-term setting, meaning that they have reached
about 1 year of age. In particular, a couple of the patients with pul-
monary atresia and an intact septum in which the pulmonary valve
was able to be perforated and allow for growth, the stents, when we
are bringing them back into the catheter laboratory, have had a
neointimal proliferation within the stent, which is a well-known
complication. However, it has been auto-amputating itself, and
the hope is that the natural course of this neointimal proliferation
will begin to take the stent out of the equation of the additional pul-
monary blood supply and not sacrifice significant saturation. The
ligation I will have to leave to my surgeons, but it is common
that, if we have to go to a Glen palliation at 6 months of age for
a right ventricle that is not growing or if it is used in a patient
who does not have the ability to have 2 sources of pulmonary blood
flow, I do believe that the ductus is ligated with the stent in place.
They crimp down the stent so that no further flow occurs.
Dr Chen. Ross, you just tie this thing off and crush the stent?
What do you do with this?
DrUngerleider.You can crush them. They do erode sometimes.
Usually, not that much flow occurs. What does happen, and it
worries me, but any time we do new things, we have to be willing
to accept the consequences of that. Anything we do has conse-
quences. You might have to do some arch reconstructions in pa-
tients who would not ordinarily undergo an arch reconstruction,
but for the most part, you can just crimp these stents. We have
also cut through them sometimes when we are doing a Fontan402 The Journal of Thoracic and Cardiovascular Surgfor patients who have had stents in the pulmonary arteries. It is
easy to cut through them, so they are there. Whether we should
be putting them in this location or if we. . One of the points I
would just say is, if we move to value-based care in which we
are not being measured by relative value units but by what is the
best we can do in using the resources, the real questionwe are going
to be asking, because we will all get paid whether we do an inter-
ventional stent or a surgical shunt (themoney comes in as revenue),
and we want to make sure that we have value, more revenue, and
less cost. The real question that we are going to be addressing
one day is what is the best time to use these and which of the pa-
tients we should not use them for, but it is a very fascinating idea.
Dr Gordon Cohen (Seattle, Wash).As one of the surgeons who
manages these stents, they are very easy to manage, as Ross said.
We can just put a (ligate) clip across it, and if you are doing a bidi-
rectional Glen as a second-stage palliation, it does not get in the
way at all. It is just like ligating the ductus at the beginning of
any other operation, but in these cases, we just use a ligate clip,
and it is quite easy to deal with.
As far as Ross’ questions go, if we think back to the history of
the Blalock-Taussig shunts when Mark DeLaval first started doing
the modified Blalock-Taussig shunt and using a Gore-Tex tube to
do it, he did not have institutional review board approval. One day
he had to make a decision that this was, in his opinion, a better
operation, and it quickly became the reference standard. If we
think about what the goals are in terms of doing a systemic to pul-
monary shunt, really all we are doing is re-creating the ductus ar-
teriosus. We cannot leave a patient taking prostaglandin for 6
months, so we are surgically re-creating the ductus arteriosus. In
this case, we are just replacing the prostaglandin with a stent,
and, frankly, it is very easy to manage. Also, what is nice about
it is that when you come back for the second-stage operation, there
is no risk of injuring the heart on re-entry; there are no adhesions to
manage. If you want to use autologous pericardium to do a part of
your reconstruction, it is easily available because it has not been
adhered down to the heart. Thus, frankly, it makes everything
very, very easy moving forward. The other point is, if you look
in the Society of Thoracic Surgeons database, the outcomes
from modified Blalock-Taussig shunts have not been so great.
There is a pretty high mortality rate associated with it, and it is
actually one of the higher mortality rate operations we do. This
is a much less eventful procedure for the patient to undergo.
They get the stent placed in the ductus. They tolerate it really quite
well, and there is no big issue with it acutely. As Agustin presented
to you, the long-term consequences are actually pretty easy to
manage as well. I think in our institution actually we are moving
toward it becoming, really, our primary intervention when a sys-
temic to pulmonary artery shunt is needed.
Dr Pranava Sinha (Washington, DC). I congratulate you on the
excellent outcomes of the ductal stent, which are much better than
those in the previous reports in which there was a very high inci-
dence of ipsilateral branch pulmonary artery problems.
I have 2 questions for you. One is, do you attribute this remark-
able result to just pure patient selection or has advancement
occurred in the technical aspect of the stenting? My second ques-
tion to you is, in your abstract, I noticed an unusually long interval
between stage 1 and stage 2—a mean of 245 days—which seems
to be longer than usual. The longer you basically stay with a stentery c January 2014
McMullan et al Congenital Heart Diseaseor a shunt, the more complications you are going to see. Can you
comment on that?
Dr Rubio. Regarding your first question, I think most of this is
patient selection. We are very rigorous about choosing which pa-
tient would benefit best from ductal stenting. We are also very
careful with deciding—it has occurred for some patients in the pul-
monary atresia group that we have noticed that the ductus arterio-
sus insertion site is not at the bifurcation point but rather is more
off to the right branch pulmonary artery or the left branch pulmo-
nary artery, where you will have a significant issue with perfusion
to 1 of the lungs. We are very careful with that. Usually, if that is
the case, we see that on the first angiogram within the ductus arte-
riosus, and we refer those patients to surgery.
Regarding your second question, that was an observation we
also made. We are not really sure why it was such a long time
difference between stage 1 and stage 2.The Journal of Thoracic and CaDr Sinha. Because I am looking at some data from our institu-
tion, and our median interstage interval has been in the range of
145 days.
Dr Rubio. There are certain patients that we, for geographic
reasons—we cover Alaska and Montana and Idaho—we
frequently do not get to them within the ideal time period that
we would like because of extraneous issues that we have to deal
with, so that skews some of the numbers, but I think for most of
the patients, especially those undergoing single ventricle pallia-
tion, those patients are brought in in more of a standard time,
with their second stage palliation occurring around 4.5 to 5 months
of age. Our numbers are a little bit skewed also, because some of
the patients have been able to potentially grow part of their right
ventricle or have these 2 sources of pulmonary blood flow and
remain stable, but it is something that we will be looking at in
the future.rdiovascular Surgery c Volume 147, Number 1 403
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